Chemclin Diagnostics Co., Ltd. (SHA:688468)
China · Delayed Price · Currency is CNY 7.39
+0.15 (2.07%)
Apr 29, 2026, 2:45 PM CST
Chemclin Diagnostics Market Cap
Chemclin Diagnostics has a market cap or net worth of 2.86 billion as of April 28, 2026. Its market cap has decreased by -2.82% in one year.
Market Cap
2.86B
Enterprise Value
2.68B
Revenue
332.68M
Ranking
n/a
PE Ratio
65.82
Stock Price
7.39
Market Cap Chart
Since April 9, 2021, Chemclin Diagnostics's market cap has decreased from 10.00B to 2.86B, a decrease of -71.43%. That is a compound annual growth rate of -21.95%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 28, 2026 | 2.86B | -1.36% |
| Dec 31, 2025 | 2.90B | 7.15% |
| Dec 31, 2024 | 2.70B | -37.53% |
| Dec 29, 2023 | 4.33B | 13.94% |
| Dec 30, 2022 | 3.80B | -47.15% |
| Dec 31, 2021 | 7.19B | -28.15% |
| Apr 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Amoy Diagnostics | 8.03B |
| Beijing Strong Biotechnologies,Inc. | 7.20B |
| Maccura Biotechnology Co.Ltd | 6.31B |
| Cowealth Medical China | 6.19B |
| SMO ClinPlus CO.,LTD. | 4.51B |
| Thalys Medical Technology Group | 4.48B |
| Guangdong Hybribio Biotech | 3.83B |
| Shanghai Labway Clinical Laboratory | 3.78B |